Results 121 to 130 of about 392,253 (296)
An autologous whole‐tumor‐cell vaccine (rWTC‐MBTA) is evaluated in murine CNS lymphoma. Subcutaneous vaccination activates dendritic cells, broadens T‐cell priming, and drives lymphocyte trafficking to brain tumors, producing durable tumor control. Longitudinal bioluminescence and adoptive‐transfer assays verify CNS engagement. Combination with anti‐PD‐
Yaping Zhang +10 more
wiley +1 more source
Osteosarcoma is the most common primary bone tumor with limited treatment options and a terrible prognosis. This review provides a comprehensive summary of the recent development of osteoimmunomodulatory implants for post‐operative osteosarcoma treatment, of which the potential utility in evoking durable anti‐osteosarcoma immunity and accelerating bone
Yilong Dong +6 more
wiley +1 more source
Improved Systemic Immunochemotherapy Employing an Oxaliplatin‐TLR7/8 Agonist Prodrug Strategy
A platinum(IV) prodrug is developed to systemically deliver the TLR7/8 agonist gardiquimod. Tumor‐targeting is mediated by an albumin‐binding maleimide, which limits premature complex activation. Ox‐Gardi‐Mal accumulates specifically in the tumor, where it activates the immune system.
Michael Gutmann +15 more
wiley +1 more source
GPCRs in CAR‐T Cell Immunotherapy: Expanding the Target Landscape and Enhancing Therapeutic Efficacy
Chimeric antigen receptor T cell therapy faces dual challenges of target scarcity and an immunosuppressive microenvironment in solid tumors. This review highlights how G protein‐coupled receptors can serve as both novel targets to expand the therapeutic scope and functional modules to enhance CAR‐T cell efficacy.
Zhuoqun Liu +11 more
wiley +1 more source
This study identifies GDF15+ TAMs as a cell subset mediating tumor regression after immunotherapy. Macrophage‐intrinsic GDF15 enhances phagocytosis and antigen cross‐presentation to CD8+ T cells through the NF‐κB signaling pathway, thereby inhibiting tumor progression.
Xinyu Zhou +9 more
wiley +1 more source
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey +6 more
wiley +1 more source
Adugnaw Zeleke Alem, Ejigu Gebeye Zeleke, Temesgen Yihunie Akalu Department of Epidemiology and Biostatistics, Institute of Public Health, College of Medicine and Health Science, University of Gondar, Gondar, EthiopiaCorrespondence: Adugnaw Zeleke Alem ...
Zeleke Alem A, Gebeye Zeleke E, Akalu TY
doaj
Model of circNrip1 (cNrip1) upregulation driving neuropathic pain mechanisms. After peripheral nerve injury, increased FUS triggers the formation and upregulation of cNrip1 in injured DRG neurons. Upregulated cNrip1 recruits SYNCRIP to the 3′‐UTR of Tlr2 mRNA by binding to both, thereby promoting SYNCRIP‐triggered Tlr2 mRNA stability and increasing ...
Xiaozhou Feng +14 more
wiley +1 more source
Backgroud The benefit of adjuvant chemotherapy for patients with stage IB lung adenocarcinoma remains unclear. We compared adjuvant chemotherapy outcomes in Asian and non-Asian stage IB lung adenocarcinoma patients using multi-source clinical data ...
Shaowei Xin +15 more
doaj +1 more source

